These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28830328)

  • 1. [Not Available].
    Riesen WF
    Praxis (Bern 1994); 2017 Aug; 106(17):921-926. PubMed ID: 28830328
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Barthelmes J; Sudano I
    Praxis (Bern 1994); 2017 Aug; 106(17):933-940. PubMed ID: 28830329
    [No Abstract]   [Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.
    Ference BA; Cannon CP; Landmesser U; Lüscher TF; Catapano AL; Ray KK
    Eur Heart J; 2018 Jul; 39(27):2540-2545. PubMed ID: 29020411
    [No Abstract]   [Full Text] [Related]  

  • 5. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New concepts in the management of dyslipidaemiaa.
    Gencer B; Rodondi N; Mach F
    Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.
    Sisson EM; Pamulapati L; Bucheit JD; Kelly MS; Dixon DL
    Pharmacotherapy; 2018 Feb; 38(2):164-171. PubMed ID: 29266309
    [No Abstract]   [Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.
    Gragnano F; Natale F; Concilio C; Fimiani F; Cesaro A; Sperlongano S; Crisci M; Limongelli G; Calabrò R; Russo M; Golia E; Calabrò P
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19(2):75-77. PubMed ID: 29251697
    [No Abstract]   [Full Text] [Related]  

  • 11. [PCSK9 inhibitors: What place in the management of dyslipidemia?].
    Sabouret P; Farnier M; Puymirat E
    Presse Med; 2019 Mar; 48(3 Pt 1):227-237. PubMed ID: 30853281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dyslipidemias : Diagnostics and management].
    Sinning D; Landmesser U
    Herz; 2017 Sep; 42(6):607-620. PubMed ID: 28791432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
    Rodriguez F; Harrington RA
    JAMA; 2016 Nov; 316(19):1967-1968. PubMed ID: 27838727
    [No Abstract]   [Full Text] [Related]  

  • 16. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
    Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
    Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.
    King P; Nicholls SJ
    Curr Cardiol Rep; 2017 Aug; 19(8):66. PubMed ID: 28643240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Bilz S
    Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
    [No Abstract]   [Full Text] [Related]  

  • 20. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V
    Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.